Medical History, Medications, and Pancreatic Cancer Risk

病史、药物和胰腺癌风险

• 批准号: 6695423
• 负责人: MARGARET MANDELSON
• 金额: $ 7.76万
• 依托单位: KAISER FOUNDATION HEALTH PLAN OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-08-01 至 2005-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6695423
• 关键词: ACE inhibitors; HMG coA reductases; Helicobacter; antineoplastics; cancer prevention; cancer risk; cholecystectomy; cholelithiasis; clinical research; diabetes mellitus; disease /therapy duration; histamine receptor; human subject; immunosuppressive; medical records; neoplasm /cancer epidemiology; nonsteroidal antiinflammatory agent; oxidoreductase inhibitor; pancreas neoplasms; pancreatitis; peptic ulcer

DESCRIPTION (provided by applicant): Risk factors for pancreatic cancer are not well established. The goal of this pilot study is to investigate the relation between medical history, medication use and pancreatic cancer in a case-control study based on medical record abstraction and electronic laboratory and pharmacy data. Our specific aims are: 1. To investigate the relation between medical conditions and pancreatic cancer risk, focusing on: a. Diabetes mellitus, including disease duration, therapy, and glycemic control. b. Pancreatic inflammation, including acute and chronic pancreatitis. c. History of peptic ulcer disease and/or infection with Helicobacter pylori (H. pylori). d. History of cholecystectomy and/or cholelithiasis. 2. To investigate the relation between the use of medications and pancreatic cancer, focusing on nonsteroidal anti-inflammatory drugs, cholesterol lowering agents including HMG-CoA reductase inhibitors and acid suppressive medications including histamine receptor antagonists and proton pump inhibitors. As a secondary specific aim we propose to examine additional medical conditions and medications in order to generate hypotheses for future studies of the epidemiology and prevention of pancreatic cancer. These include evaluation of medical conditions such as irritable bowel syndrome, allergies and asthma as well as medications including immunosuppressive medications and angiotensin converting enzyme inhibitors. To meet these specific aims we propose to conduct a case-control study of pancreatic cancer comprised of 250 newly diagnosed cases and 1,000 controls in the defined population of Group Health Cooperative, a large health maintenance organization. Data on prior medical conditions and medications will be collected through abstraction of traditional and computerized medical records, including electronic laboratory and pharmacy data. Study strengths include the availability of uniformly collected, long-term medical and pharmacy data and the availability of data on important covariates, including smoking. The proposed study will provide a unique opportunity to investigate the role of medical conditions and medications in pancreatic tumorigenesis and to generate new insights into the mechanisms that result in pancreatic cancer.

描述（由申请人提供）： 胰腺癌的危险因素尚未明确。这项试点研究的目标是在基于病历摘要以及电子实验室和药房数据的病例对照研究中调查病史、药物使用和胰腺癌之间的关系。 我们的具体目标是： 1. 调查医疗状况与胰腺癌风险之间的关系，重点关注： 一个。糖尿病，包括病程、治疗和血糖控制。 b.胰腺炎症包括急性和慢性胰腺炎。 c.有消化性溃疡病史和/或幽门螺杆菌（H. pylori）感染史。 d.有胆囊切除术和/或胆石症史。 2. 探讨药物使用与胰腺癌的关系，重点关注非甾体抗炎药、降胆固醇药物（包括HMG-CoA还原酶抑制剂）和抑酸药物（包括组胺受体拮抗剂和质子泵抑制剂）。 作为次要具体目标，我们建议检查其他医疗状况和药物，以便为胰腺癌的流行病学和预防的未来研究提出假设。其中包括评估肠易激综合症、过敏和哮喘等医疗状况以及免疫抑制药物和血管紧张素转换酶抑制剂等药物。 为了实现这些具体目标，我们建议开展一项胰腺癌病例对照研究，该研究由大型健康维护组织 Group Health Cooperative 的指定人群中的 250 名新诊断病例和 1,000 名对照者组成。有关先前医疗状况和药物治疗的数据将通过提取传统和计算机化医疗记录（包括电子实验室和药房数据）来收集。研究优势包括统一收集的长期医疗和药学数据的可用性以及重要协变量（包括吸烟）数据的可用性。拟议的研究将提供一个独特的机会来研究医疗条件和药物在胰腺肿瘤发生中的作用，并对导致胰腺癌的机制产生新的见解。